… from diagnosis of heart failure were all chosen as recognized markers of severity of heart
failure; ICDs are not indicated in patients with more severe heart failure symptoms because of …

… , hospitalization for heart failure, or an urgent visit resulting in intravenous therapy for heart
failure. The cumulative incidences of the primary outcome, hospitalization for heart failure, …

… Dapagliflozin reduces the risk of de novo heart failure (HF) in diabetics, and it has shown to
improve … The beneficial effects of dapagliflozin on HF are independent of diabetes status and …

… To better understand the effects of dapagliflozin on cause-specific mortality across the
spectrum of EF, we pooled data from the DAPA-HF and DELIVER trials, which both randomly …

… of mortality and heart failure hospitalization and improved symptoms in patients with heart
failure and reduced ejection fraction. We examined the effects of dapagliflozin according to …

… Moreover, the beneficial effects of dapagliflozin were seen regardless of patients’ usual
HF medications. Dapagliflozin was generally well tolerated and is a valuable option for the …

… To compare the effects of dapagliflozin vs placebo on the primary outcome and secondary
clinical outcomes in men and women, respectively, time-to-event data were evaluated with the …

… The main objective of this work was to determine the cardiac effects of dapagliflozin in
patients with HF and T2DM to help to explain the substantial improvements in HF outcomes seen …

… The impact of heart failure (HF) duration on outcomes and … standard therapy, in patients with
heart failure (HF) and reduced … We also analyzed the effects of dapagliflozin, compared with …

… Heart Failure) trials, which evaluated the effects of dapagliflozin in HFrEF and heart failure
with mildly reduced ejection fraction (HFmrEF)/heart failure with preserved ejection fraction (…